IRF3 and metabolic dysfunction-associated steatotic liver disease: Compared to patients with NAFLD, patients with NASH show a significant increase in LPS and free fatty acid (FFA), as well as an increase in TLR4 mRNA and interferon regulatory factor 3 (IRF-3) in the myeloid differentiation factor 88-independent signaling pathway.